摘要
目的 :分析首次治疗的精神分裂症患者抗精神病药 (APS)急性期治疗期间血糖改变及其与体重体脂指标间的关系。 方法 :测定 4 6例患者 (男 2 7例 ,女 19例 )APS单药治疗 10周前后空腹血糖和餐后 2h血糖 ;观察治疗前后体重指数 (BMI)和腰臀比率 (WHR) ,并采用磁共振测定其中 4 0例患者治疗前后腹部脂肪分布。 结果 :患者治疗 10周后餐后 2h血糖明显增高 ,葡萄糖耐量低减 (IGT)发生率增加。治疗前餐后 2h血糖水平与体重体脂指标呈正相关 ;治疗 10周后 ,餐后 2h血糖水平与体重体脂指标无相关。 结论 :APS急性期治疗可致精神分裂症患者血糖异常 ;
Objective:To investigate the effects of antipsychotic agents (APS) therapy on glucose regulation and the relationship with index of weight and body fat distribution in previously untreated patients with schizophrenia. Method:Fasting and 2-hour after breakfast plasma glucose levels were measured in 46 Chinese Han untreated patients with schizophrenia receiving risperidone or chlorpromazine before and after 10-week treatment.Body weight, body mass index (BMI) and waist-hip-ratio (WHR) were also measured for whole subjects.Abdominal body fat was determined by MRI in 40 of schizophrenic patients before and after 10-week treatment. Results:There was a significant elevation in 2-hour breakfast plasma glucose levels in schizophrenic patients after 10-week treatment compared with untreated patients,with a substantial increase in morbidity of IGT. Before treatment,after 2-hour breakfast plasma glucose level was positively correlated with index of weight and body fat distribution.However,Such correlation disappeared after 10-week treatment. Conclusion:APS acute treatment may impair glucose regulation of schizophrenic patients. Abnormality of glucose regulation correlated with change of weight and body fat distribution.
出处
《临床精神医学杂志》
2004年第1期1-3,共3页
Journal of Clinical Psychiatry
基金
国家自然科学基金资助项目 (课题号 3 0 170 3 44)
关键词
抗精神病药
体重
腹型肥胖
代谢综合征
精神分裂症
Antipsychotic agents
Body weight
Body fat distribution
Metabolic syndrome
Schizophrenia
